Pleiotropic Effects of Platelet P2Y12 Receptor Inhibitors: Fact or Fiction?

Athanasios      Moulias; Ioanna      Xanthopoulou; Dimitrios      Alexopoulos

Abstract

P2Y₁₂ inhibitors constitute an essential part of the antithrombotic treatment, with proven clinical benefit in acute coronary syndromes and after percutaneous coronary interventions. Substantial evidence has emerged that, apart from their primary antiplatelet action, P2Y₁₂ receptor inhibitors exhibit several off-target effects. In this review, we present the supporting evidence of P2Y₁₂ inhibitors’ pleiotropic actions, discuss their clinical implications and underscore the necessity for further research on this issue.

Keywords: Clopidogrel, off-target effects, pleiotropic, P2Y12 inhibitors, prasugrel, ticagrelor.

« Previous

Rights & Permissions Print Cite

Current Pharmaceutical Design

Title:Pleiotropic Effects of Platelet P2Y₁₂ Receptor Inhibitors: Fact or Fiction?

Volume: 20 Issue: 28

Author(s): Athanasios Moulias, Ioanna Xanthopoulou and Dimitrios Alexopoulos

Affiliation:

Keywords: Clopidogrel, off-target effects, pleiotropic, P2Y12 inhibitors, prasugrel, ticagrelor.

Abstract: P2Y₁₂ inhibitors constitute an essential part of the antithrombotic treatment, with proven clinical benefit in acute coronary syndromes and after percutaneous coronary interventions. Substantial evidence has emerged that, apart from their primary antiplatelet action, P2Y₁₂ receptor inhibitors exhibit several off-target effects. In this review, we present the supporting evidence of P2Y₁₂ inhibitors’ pleiotropic actions, discuss their clinical implications and underscore the necessity for further research on this issue.

Export Options

Export File:

RIS (for EndNote, Reference Manager, ProCite)

BibTeX

Text

Content:

Citation Only

Citation and Abstract

About this article

Cite this article as:

Moulias Athanasios, Xanthopoulou Ioanna and Alexopoulos Dimitrios, Pleiotropic Effects of Platelet P2Y₁₂ Receptor Inhibitors: Fact or Fiction?, Current Pharmaceutical Design 2014; 20 (28) . https://dx.doi.org/10.2174/1381612820666140414211543

DOI https://dx.doi.org/10.2174/1381612820666140414211543	Print ISSN 1381-6128
Publisher Name Bentham Science Publisher	Online ISSN 1873-4286

About this journal

Call for Papers in Thematic Issues

Submission closes on : 30 July, 2024

"Tuberculosis Prevention, Diagnosis and Drug Discovery"

The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more

Guest Editor(s): Dr. M Pinheiro

Submission closes on : 18 September, 2024

Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions

Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more

Guest Editor(s): Dr. Sidharth Mehan

Submission closes on : 29 September, 2024

Emerging and re-emerging diseases

Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more

Guest Editor(s): Marcos Roberto Tovani Palone

Submission closes on : 30 June, 2024

Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances

In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more

Guest Editor(s): Dr. MF Chedid